click below
click below
Normal Size Small Size show me how
WEEK 23:
BREAST CANCER PLENARY:
| Question | Answer |
|---|---|
| limitations of mammogram | subjective lack of consistency in positioning missing cancers in periphery if exposure not adequate dense breast can be uncomfortable |
| MDT roles in this case | breast surgeon oncologist pathologist radiologist cancer nurse specialists mammographers plastic surgeons MDT coordinator research nurses |
| how to break bad news | setting (quiet room with privacy no distractions) assess patients perception (before you tell ask) warning shots to lessen shock address patients emotions with empathy offer contact number of key worker offer follow up consultation |
| surgery options | breast conservation surgery (wide local excision with oncoplastic procedures) or mastectomy (with or without reconstruction) with reconstruction being immediate or delayed |
| stages 0,1,2 (first stage of staging TNM) | early stage (cancer not beyond breast and regional LNs) |
| stage 3 (2nd stage of staging TNM) | locally advanced breast cancer, inflammatory breast cancer |
| last stage of staging TNM | advanced breast cancer |
| stages of staging TNM | early stage locally advanced advanced |
| prognostic is based on/ scored using | nottingham prognostic index |
| endocrine treatment types | first line and second line |
| first line endocrine treatment | SERM (selective estrogen receptor modulator) eg tamoxifen and raloxifene Aromatase inhibitors eg letrozole, anastrozole, and exemestane |
| second line endocrine treatment SERM | everolimus (PI3K/AKTmTOR pathway down regulator) Palbociclib, ribociclib (CDK4/ 6 inhibitors) |
| examples of anti HER2 treatment | trastuzumab (herceptin) and pertuzumab (anything ending in MAB/ nib) |
| breast cancer treatment depends on | locoregional recurrence or distant metastasis |